This promising outcome was comparable to the results achieved with standard HER2-targeted therapy combined with chemotherapy, while significantly reducing adverse effects and improving patients’ quality of life.24 These findings highlight the potential of chemotherapy-free regimen based on multi-pathway inhibition as a viable and more tolerable alternative for a substantial subset of patients with HR+/HER2+ breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.